Meta CEO Zuckerberg Says AI Agent Development Has Slowed Despite Massive AI Investment 
Turkey Vehicle Sales Fall 11.4% in June as Auto Market Weakens 
Asian Currencies Stay Under Pressure as Dollar Holds Near 13-Month High Ahead of U.S. Jobs Report 
US Resumes Dollar Shipments to Iraq After Months-Long Suspension 
Tesla Q2 Deliveries Lift Chinese Auto Suppliers as EV Demand Improves 
Japan Signals Surprise Yen Intervention Strategy as BOJ Hawkish Stance Puts FX Traders on Alert 
New Zealand Consumer Confidence Rises in June as Inflation Expectations Ease 
Lockheed Martin Emerges as Frontrunner to Acquire Ultra Maritime in $3.5 Billion Defense Deal 
Asian Stocks Slide as Chip Shares Tumble Ahead of Key U.S. Jobs Report 
OpenAI Proposes 5% U.S. Government Stake Amid AI Policy Talks 
Apple Expands iPhone Lineup, Boosts Foldable iPhone Production Plans Through 2027 
Gold Price Surges Above $4,120 as Weak US Jobs Data Lowers Fed Rate Hike Expectations 
South Korea Warns Won Is Undervalued, Boosts FX Coordination With Japan 
Gold Price Today: Bullion Heads for First Weekly Gain as Weak U.S. Jobs Data Eases Rate Hike Fears 
Australia Trade Balance Swings to Surprise Deficit as Imports Outpace Exports in May 
Kioxia Bets on AI Memory Boom With Next-Gen NAND Production in Japan 
Trump Administration to Launch Voluntary AI Standards for Frontier Models 
KT Corp. has collaborated with US-based NeuroSigma Inc. to build a business model and technology for electronic medicine to treat neurological disorders, such as attention deficit hyperactivity disorder (ADHD), depression, and epilepsy.
Under the partnership, KTS will support the development of the next version of NeuroSigma's external trigeminal nerve stimulation (eTNS®) system while producing and commercializing the device in South Korea.
NeuoSigma is credited for developing the first device cleared by the US Food and Drug Administration to treat pediatric ADHD--the Monarch external Trigeminal Nerve Stimulation system,
The telecom operator said NeuoSigma's pediatric ADHD electronic treatment has fewer side effects than other existing medication and is set to receive further clearance from the FDA on depression and epilepsy treatment using the technology.
